NASDAQ
AtriCure, Inc. (ATRC)
♥ 649 Thanks from members
AtriCure, Inc. (ATRC) demonstrates robust financial and operational progress, highlighted by double-digit revenue growth, expanding gross margins, and a return to GAAP profitability in Q2 2026, though rising catheter-based PFA competition and insider share trimming warrant selective caution from investors.